Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company is focused primarily on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are caused by naturally occurring toxic chemical species known as free aldehydes. The Company has developed a series of product candidates that are designed specifically to trap and allow for the degradation of free aldehydes. The Company's most advanced product candidate is an eye drop formulation of NS2, which is under development for the treatment of Sjogren-Larsson Syndrome (SLS). The Company has completed a double-masked, placebo-controlled, Phase I clinical testing of 0.25% and 0.5% NS2 administered as an eye drop for safety and tolerability in approximately 48 healthy volunteers. Data from the Phase I study demonstrated that NS2 was well tolerated in all subjects throughout the duration of the study.
Company Growth (employees)
Lexington, US
Size (employees)
6 (est)
Aldeyra Therapeutics was founded in 2004 and is headquartered in Lexington, US

Aldeyra Therapeutics Office Locations

Aldeyra Therapeutics has an office in Lexington
Lexington, US (HQ)
131 Hartwell Ave

Aldeyra Therapeutics Data and Metrics

Aldeyra Therapeutics Financial Metrics

Numbers are in $, USD

Net income (FY, 2016)

(18.7 m)

Market capitalization (26-May-2017)

29.7 m

Closing share price (26-May-2017)


Cash (31-Dec-2016)

12 m
Aldeyra Therapeutics's current market capitalization is $29.7 m.
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

R&D expense

3.7 m7.6 m13.2 m

General and administrative expense

3.6 m4.4 m5.5 m

Operating expense total

(7.3 m)(12 m)(18.7 m)

Interest expense

(244.2 k)(112.3 k)(105.5 k)

Interest income

311.1 k102 k

Net Income

(9.6 m)(12.1 m)(18.7 m)
Numbers are in $, USDFY, 2014FY, 2015FY, 2016


8.5 m14.6 m12 m


232.6 k497.6 k218.7 k

Current Assets

8.8 m28.1 m25.1 m

Total Assets

8.8 m28.2 m25.2 m

Accounts Payable

341.3 k851.2 k275.4 k

Current Liabilities

1.3 m2.1 m2.3 m

Additional Paid-in Capital

1.1 m83.5 m98.9 m

Retained Earnings

(46.5 m)(58.6 m)(77.3 m)

Total Equity

6.3 m24.9 m21.6 m

Financial Leverage

1.4 x1.1 x1.2 x
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Net Income

(5.2 m)(12.1 m)(18.7 m)

Depreciation and Amortization

1.1 k18.8 k35.8 k


(224.2 k)(265 k)278.9 k

Accounts Payable

(559)509.9 k(575.7 k)

Cash From Operating Activities

5.3 m6.1 m(15.1 m)

Cash From Investing Activities

(14.1 k)(13 m)(225.2 k)

Cash From Financing Activities

10.1 m28.5 m12.7 m

Interest Paid

96.8 k74.3 k78.1 k
Y, 2016

Financial Leverage

1.2 x

Aldeyra Therapeutics Operating Metrics

FY, 2016

Patents (US)


Patents Pending


Aldeyra Therapeutics Market Value History

Aldeyra Therapeutics Online and Social Media Presence

Aldeyra Therapeutics Company Life and Culture

You may also be interested in